Gilead Sciences (GILD) Receivables - Other (2018 - 2026)

Gilead Sciences (GILD) has reported Receivables - Other for 9 consecutive years, with $589.0 million the latest figure, recorded in Q1 2026.

• Receivables - Other for Q1 2026 came in at $589.0 million, up 93.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $589.0 million (up 93.75% YoY), and the FY2025 annual result was $629.0 million, up 127.08% from the prior year.
• Receivables - Other was $589.0 million for Q1 2026 at Gilead Sciences, down from $629.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $695.0 million in Q3 2025 and troughed at $117.0 million in Q4 2023.
• Average Receivables - Other over 5 years is $264.0 million, with a median of $167.0 million recorded in 2022.
• Year-over-year, Receivables - Other tumbled 31.58% in 2023 and surged 277.72% in 2025.
• Over 5 years, Receivables - Other stood at $171.0 million in 2022, then sank by 31.58% to $117.0 million in 2023, then soared by 136.75% to $277.0 million in 2024, then jumped by 127.08% to $629.0 million in 2025, then fell by 6.36% to $589.0 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $589.0 million in Q1 2026, $629.0 million in Q4 2025, and $695.0 million in Q3 2025.